Cerulean Pharma Inc. (DARE) Receives $3.00 Consensus Price Target from Brokerages

Shares of Cerulean Pharma Inc. (NASDAQ:DARE) have been given a consensus recommendation of “Hold” by the six research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $3.00.

Separately, ValuEngine raised shares of Cerulean Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, July 22nd.

Cerulean Pharma (DARE) traded down 2.90% during trading on Friday, reaching $2.68. The company’s stock had a trading volume of 18,878 shares. Cerulean Pharma has a 52 week low of $2.63 and a 52 week high of $35.80. The firm has a 50-day moving average price of $4.87 and a 200-day moving average price of $7.60. The firm’s market capitalization is $7.78 million.

TRADEMARK VIOLATION NOTICE: This story was posted by [[site]] and is the sole property of of [[site]]. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at [[permalink]].

Cerulean Pharma Company Profile

Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.